Head to head
AxoGen vs Abbott Laboratories
Side-by-side on the measures that matter, with a plain-English read. Full detail: AXGN · ABT
AXGN
AxoGen
36.04-0.74%
1-year price shape — +113% over the period
Quant Rating D · 95/100
vs
ABT
Abbott Laboratories
98.73+0.58%
1-year price shape — -24% over the period
Quant Rating E · 15/100
1-year performance, rebased to 100
Abbott Laboratories edges it on the scoreable measures. Abbott Laboratories pays the highest dividend yield; Abbott Laboratories earns the most per share.
| AXGN | ABT | |
|---|---|---|
| Snapshot | ||
| Sector | -- | Medical Devices |
| Last price | 36.04 | 98.73 |
| Change today | -0.74% | +0.58% |
| 1-year return | +113.3% | -24.1% |
| Market cap | $2.11B | $170.84B |
| 52-week range | 15.27 – 52.91 | 81.39 – 130.33 |
| Valuation | ||
| P/E (TTM) | -53.79 | 31.95 |
| P/E percentile, own 5-yr range | 35th | 62nd |
| P/B | 8.25 | 3.34 |
| Dividend yield | 0.00% | 2.47% |
| Profitability & growth | ||
| EPS (TTM) | -0.34 | 3.72 |
| Net profit (TTM) | $-19.95M | $6.44B |
| Revenue (TTM) | $251.17M | $46.59B |
| Revenue growth (YoY) | +23.1% | +13.0% |
| Gross margin | 74.6% | 56.6% |
| Operating margin | -5.1% | 15.8% |
| Net margin | -13.4% | 11.6% |
| Free cash flow (TTM) | $6.51M | $7.82B |
| Ownership & sentiment | ||
| Institutional ownership | 99.2% | 81.2% |
| Insider activity (12mo) | 29 buy / 18 sell | 36 buy / 12 sell |
| Short interest (% of float) | 6.9% | 1.1% |
| Analyst consensus | 100% buy (9) | 100% buy (14) |
| Analyst price target | $54 (+50%) | $125 (+26%) |
| StockVane view | ||
| StockVane Quant Rating | D (95) | E (15) |
| Company | ||
| Employees | 622 | 115,000 |
| Founded | 1977 | 1888 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.